Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Clinical Study Objective: To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency Study Method: Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.
Epistemonikos ID: fb550ff6d42e0dc488838a2461ab4e1069ca2f78
First added on: May 08, 2024